Home Pharma News CDC recommends Novavax’s COVID-19 vaccine to be used as primary series option for adolescents

CDC recommends Novavax’s COVID-19 vaccine to be used as primary series option for adolescents

by Vaishali Sharma
vaccines

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., signed a decision letter recommending that Novavax’s COVID-19 vaccination be utilised as a secondary series option for adolescents aged 12 to 17. This advice follows the FDA’s approval of the vaccine for this age range for emergency use.

Novavax’s COVID-19 vaccine, which is currently accessible, is an essential instrument in the pandemic and offers teenagers with a more familiar form of COVID-19 vaccine technology. Having a variety of vaccinations provides the public, governments, and vaccine providers with greater alternatives and flexibility.

Also Read: Covid case update: India reports 6,168 new cases

The COVID-19 vaccine from Novavax contains harmless COVID-19 viral proteins as well as an adjuvant, which aids the immune system’s future response to the virus. Vaccines that employ protein subunit technology, such as the Novavax COVID-19 vaccine, have been used in the United States for more than 30 years, beginning with the first approved hepatitis B vaccination.

Other protein subunit vaccines used in the United States today include those to protect against influenza and whooping cough (acellular pertussis).

Follow Medically Speaking on Twitter Instagram Facebook

You may also like